Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay

Clinical and Vaccine Immunology

Volumn 20, Issue 7, 2013, Pages 986-997

  Lu, Hang ^a   Catania, Jason ^a   Baranji, Katalin ^a   Feng, Jie ^a   Gu, Mili ^a   Lathey, Janet ^a   Sweeny, Diane ^a   Sanford, Hannah ^a   Sapru, Kavita ^a   Patamawenu, Terry ^a   Chen, June Home ^a   Ng, Alan ^a   Fesseha, Zenbework ^a   Kluepfel Stahl, Stefanie ^a   Minang, Jacob ^a   Alleva, David ^a  

^a Emergent Biosolutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; HISTIDINE; METHIONINE; REAGENT; RECOMBINANT LETHAL FACTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACILLUS ANTHRACIS; BIOASSAY; BLOOD SAMPLING; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY TEST; DILUTION CURVE; DRUG EFFECT; EXPRESSION VECTOR; IMMUNIZATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXIN NEUTRALIZATION ASSAY;

ANIMALS; ANTHRAX; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; CELL SURVIVAL; FEMALE; MACACA FASCICULARIS; MACROPHAGES; MALE; MICE; NEUTRALIZATION TESTS; RABBITS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 84880464443     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00046-13     Document Type: Article

References (28)

1. Tournier JN, Rossi PS, Quesnel-Hellmann A, Baldari CT. 2009. Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol. Aspects Med. 30:456-466.
2. Moayeri M, Leppla SH. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. 30:439-455.
3. Moayeri M, Sastalla I, Leppla SH. 2012. Anthrax and the inflammasome. Microbes Infect. 14:392-400.
4. Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, Getz MA, Liu S, Sastalla I, Leppla SH, Moayeri M. 2012. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog. 8:e1002638. doi:10.1371/journal.ppat.1002638.
5. Cybulski RJ, Jr, Sanz P, O'Brien AD. 2009. Anthrax vaccination strategies. Mol. Aspects Med. 30:490-502.
6. Friedlander AM, Little SF. 2009. Advances in the development of nextgeneration anthrax vaccines. Vaccine 27(Suppl. 4):D28-D32.
7. Bellanti JA, Lin FY, Chu C, Shiloach J, Leppla SH, Benavides GA, Karpas A, Moayeri M, Guo C, Robbins JB, Schneerson R. 2012. Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis. Clin. Vaccine Immunol. 19:140-145.
8. Centers for Disease Control and Prevention. 2010. Use of anthrax vaccine in the United States; recommendation of the Advisory Committee on Immunization Practices, 2009.MMWRMorb. Mortal. Wkly. Rep. 59:1-30.
9. U. S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. 2009. Guidance for industry; animal models- essential elements to address efficacy under the animal rule. FDA, Rockville, MD. http://www.fda.gov/cber/guidelines .htm.
10. Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, Quinn CP, Nuzum EO. 2012. Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci. Transl. Med. 4151ra126. doi:10.1126/scitranslmed.3004073.
11. Crowe SR, Garman L, Engler RJ, Farris AD, Ballard JD, Harley JB, James JA. 2011. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine 29:3670-3678.
12. Hepburn MJ, Hugh DE, Simpson AJ, Brenneman KE, Bailey N, Wilkinson L, Hornby R, Mateczun AJ, Bell MG, Baillie LW. 2007. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine 25:6089-6097.
13. Smith K, Crowe SR, Garman L, Guthridge CJ, Muther JJ, McKee E, Zheng NY, Farris AD, Guthridge JM, Wilson PC, James JA. 2012. Human monoclonal antibodies generated following vaccination with AVAprovide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine 30:4276-4283.
14. Taft SC, Weiss AA. 2008. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin. Vaccine Immunol. 15:71-75.
15. Omland KS, Brys A, Lansky D, Clement K, Lynn F. 2008. Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species. Clin. Vaccine Immunol. 15:946-953.
16. Pitt ML, Little S, Ivins BE, Fellows P, Boles J, Barth J, Hewetson J, Friedlander AM. 1999. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 87:304.
17. Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430.
18. Hering D, Thompson W, Hewetson J, Little S, Norris S, Pace- Templeton J. 2004. Validation of the anthrax lethal toxin neutralization assay. Biologicals 32:17-27.
19. Li H, Soroka SD, Taylor TH, Jr, Stamey KL, Stinson KW, Freeman AE, Abramson DR, Desai R, Cronin LX, Oxford JW, Caba J, Pleatman C, Pathak S, Schmidt DS, Semenova VA, Martin SK, Wilkins PP, Quinn CP. 2008. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J. Immunol. Methods 333: 89-106.
20. Brady RA, Verma A, Meade BD, Burns DL. 2010. Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays. Clin. Vaccine Immunol. 17:1390-1397.
21. Castelan-Vega J, Corvette L, Sirota L, Arciniega J. 2011. Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay. Clin. Vaccine Immunol. 18:349-351.
22. Hughes MA, Burns DL, Juris SJ, Tang WJ, Clement KH, Eaton LJ, Kelly-Cirino CD, McKee ML, Powell BS, Bishop BL, Rudge TL, Shine N, Verma A, Willis MS, Morse SA. 2009. The case for developing consensus standards for research in microbial pathogenesis: Bacillus anthracis toxins as an example. Infect. Immun. 77:4182-4186.
23. Ngundi MM, Meade BD, Lin TL, Tang WJ, Burns DL. 2010. Comparison of three anthrax toxin neutralization assays. Clin. Vaccine Immunol. 17:895-903.
24. Parreiras PM, Sirota LA, Wagner LD, Menzies SL, Arciniega JL. 2009. Comparability of ELISA and toxin neutralization to measure immunogenicity of protective antigen in mice, as part of a potency test for anthrax vaccines. Vaccine 27:4537-4542.
25. Verma A, Wagner L, Stibitz S, Nguyen N, Guerengomba F, Burns DL. 2008. Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay. Clin. Vaccine Immunol. 15:1737-1741.
26. Park S, Leppla SH. 2000. Optimized production and purification of Bacillus anthracis lethal factor. Protein Expr. Purif. 18:293-302.
27. Gupta PK, Moayeri M, Crown D, Fattah RJ, Leppla SH. 2008. Role of N-terminal amino acids in the potency of anthrax lethal factor. PLoS One 3:e3130. doi:10.1371/journal.pone.0003130.
28. Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, DeMuria D, Ransom J, Quinn J, Nabors GS, Nielsen CJ. 2011. Marked enhancement of the immune response to BioThrax (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 29:6313-6320.